Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.40 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17686007 | 0.86 | STS (0.47) | STSKDM4EPKMATMNR1H2 | |
| SCHEMBL4304594 | 0.85 | CXCR4 (0.44) | KDM4EPKMNR1D1HDAC8 | |
| SCHEMBL1682323 | 0.84 | OPRD1 (0.52) | STSKDM4EPKMMETTL3LMNA | |
| SCHEMBL25650104 | 0.84 | OPRD1 (0.52) | STSKDM4EPKMMETTL3LMNA | |
| SCHEMBL28111647 | 0.79 | STS (0.43) | JAK2JAK1STSKDM4EPKM | |
| SCHEMBL9899722 | 0.79 | KDM4E (0.39) | STSKDM4EPKMATMNR1H2 | |
| SCHEMBL8651537 | 0.77 | NAMPT (0.61) | JAK2JAK1STSKDM4EPKM | |
| SCHEMBL496466 | 0.77 | JAK2 (0.39) | JAK2JAK1STSKDM4EPKM | |
| SCHEMBL16080305 | 0.76 | NR1H2 (0.51) | JAK2JAK1STSABCB1NR1H2 | |
| SCHEMBL2933059 | 0.76 | JAK2 (0.41) | JAK2JAK1STSKDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149711-A1 | PIPERIDINE DERIVATIVES USED AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED | 2012-06-14 | — | — | US | disclosed |
| US-20120149711-A1 | PIPERIDINE DERIVATIVES USED AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED | 2012-06-14 | — | — | US | disclosed |
| US-20110053979-A1 | PYRIDINE DERIVATIVES USED TO TREAT OREXIN RELATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| US-20110053979-A1 | PYRIDINE DERIVATIVES USED TO TREAT OREXIN RELATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| WO-2009124956-A1 | PYRIDINE DERIVATIVES USED TO TREAT OREXIN RELATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149711-A1 | PIPERIDINE DERIVATIVES USED AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, OXTR | JAK2 2728/4885JAK1 4829/4885STS 4388/4885 |
| US-20110053979-A1 | PYRIDINE DERIVATIVES USED TO TREAT OREXIN RELATED DISORDERS | HCRTR2, HCRTR1, NPY4R | JAK2 2701/4885JAK1 3704/4885STS 4162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.